Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiosarcomas and taxanes.

Nicolas Penel1, Amélie Lansiaux, Antoine Adenis

  • 1Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, Lille 59020, France. n-penel@o-lambret.fr

Current Treatment Options in Oncology
|December 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of HIV epidemic trends and diagnostic delays in French Guiana: how can we make further progress?

BMC infectious diseases·2026
Same author

Profiles and outcomes of untreated people with HIV in French Guiana: progress towards 95-95-95 targets.

Archives of public health = Archives belges de sante publique·2026
Same author

Prevalence of HIV-associated histoplasmosis in the Guiana Shield: A prospective study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.

Emerging infectious diseases·2026
Same author

A multicentric cross-sectional survey to assess cardiovascular risk factors among persons working in informal gold mines in French-Guiana.

BMC public health·2026
Same author

Patients from Remote Health Centers Referred to Cayenne Emergency Department: A One-Year Observational Study.

The American journal of tropical medicine and hygiene·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Weekly paclitaxel shows promise for treating advanced angiosarcomas (AS), a rare cancer. This approach may improve outcomes for patients with unresectable or metastatic AS, warranting further investigation.

Area of Science:

  • Oncology
  • Medical Malignancies

Background:

  • Angiosarcomas (AS) are rare, aggressive cancers with limited treatment options.
  • Current metastatic AS treatment relies on doxorubicin, offering modest survival benefits.

Purpose of the Study:

  • To evaluate the efficacy of weekly paclitaxel in patients with unresectable or metastatic angiosarcomas.
  • To assess the potential of taxanes as a treatment for AS.

Main Methods:

  • A Phase II clinical trial conducted by the French Sarcoma Group.
  • Treatment involved weekly paclitaxel administration.
  • Response assessment included non-progression rates and histological evaluation.

Main Results:

  • A non-progression rate of 78% was observed after 2 cycles of weekly paclitaxel.

Related Experiment Videos

  • Complete histological responses were achieved in 3 out of 30 patients.
  • Retrospective studies and case reports suggest taxane efficacy.

    • Conclusions:

    • Weekly paclitaxel demonstrates potential benefit in unresectable or metastatic angiosarcomas.
    • Further studies are needed to confirm the survival impact of weekly paclitaxel.
    • The role of taxanes in multidisciplinary AS treatment requires further assessment.